INT351509

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.70
First Reported 2010
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 19
Total Number 52
Disease Relevance 29.01
Pain Relevance 0.63

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (IKBKAP) nucleolus (IKBKAP) nucleus (IKBKAP)
protein complex assembly (IKBKAP) DNA binding (IKBKAP) cytoplasm (IKBKAP)
Anatomy Link Frequency
neuronal 1
leukocytes 1
IKBKAP (Homo sapiens)
Pain Link Frequency Relevance Heat
Potency 52 98.50 Very High Very High Very High
Pain 52 88.52 High High
Peripheral nervous system 18 65.44 Quite High
imagery 36 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Familial Dysautonomia 4728 100.00 Very High Very High Very High
Apoptosis 70 98.80 Very High Very High Very High
Disease 266 96.04 Very High Very High Very High
Gastric Motility Disorder 18 95.20 Very High Very High Very High
Rare Diseases 36 95.16 Very High Very High Very High
Toxicity 170 94.04 High High
Cognitive Disorder 238 91.36 High High
Hypertension 18 91.24 High High
Pressure Volume 2 Under Development 18 90.20 High High
Pneumonia 34 90.16 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Long-term treatment with PS led to a significant increase in IKAP protein levels in these cells.
Positive_regulation (increase) of IKAP protein
1) Confidence 0.70 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC3012102 Disease Relevance 0.72 Pain Relevance 0
We demonstrated that phosphatidylserine significantly increased the levels of normal IKAP mRNA and protein.
Positive_regulation (increased) of IKAP mRNA
2) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 1.19 Pain Relevance 0
Further, long-term treatment of FD cells led to a significant increase in the amount of IKAP protein.
Positive_regulation (increase) of IKAP protein associated with familial dysautonomia
3) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.86 Pain Relevance 0
Although the increase in transcription level was not specific to the IKAP gene, its positive effect on the level of IKAP is unquestionable.
Positive_regulation (effect) of IKAP
4) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.54 Pain Relevance 0
In the heterozygous cell line, PS treatment induced a slight increase in IKAP mRNA (data not shown).
Positive_regulation (increase) of IKAP mRNA
5) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.17 Pain Relevance 0
As shown in Figure 3A, PS treatment increased the level of IKAP mRNA by 1.5 fold at 3 days, 1.7 fold at 7 days, and 2.5 fold after 14 days compared to levels in untreated cells.
Positive_regulation (increased) of IKAP mRNA
6) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.30 Pain Relevance 0
Since PS treatment increased the amount of the wild-type IKAP mRNA and protein present in FD cells, we obtained three additional food supplements and tested their effect on splicing.
Positive_regulation (increased) of IKAP mRNA associated with familial dysautonomia
7) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.67 Pain Relevance 0
Increasing the expression level of IKAP mRNA over a certain threshold leads to an increase in full-length IKAP protein levels.
Positive_regulation (Increasing) of IKAP mRNA
8) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.64 Pain Relevance 0
At 200 µg/ml PS, the increase was 1.5 fold, and at 300 µg/ml a 1.2-fold increase in wild-type IKAP mRNA levels was observed.
Positive_regulation (increase) of IKAP mRNA
9) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.35 Pain Relevance 0
Treatment with GPC did not significantly increase the amount of wild-type IKAP mRNA (Figure 6B).
Neg (not) Positive_regulation (increase) of IKAP mRNA
10) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.64 Pain Relevance 0.04
Rather PS acted by increasing levels of transcription of this gene; increased levels of mRNA led to elevation of the level of the normal IKAP protein.
Positive_regulation (elevation) of IKAP protein
11) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.94 Pain Relevance 0
Based on our current knowledge of FD and what is known so far about IKAP, we presume that the key for effective therapy of FD is increasing the amount of the normal, functional IKAP protein.
Positive_regulation (increasing) of IKAP protein associated with familial dysautonomia
12) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.60 Pain Relevance 0
We sought substances already proven safe for clinical use that would increase the levels of wild-type IKAP mRNA in cell lines created from cells taken from FD patients in order to identify potential treatments.
Positive_regulation (increase) of IKAP mRNA associated with familial dysautonomia
13) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 1.04 Pain Relevance 0
The divergence of our altered genes due to PS treatment from those reported in the literature in cells without IKAP indicate the unique mechanism of action that results in the PS-induced increase in IKAP levels.
Positive_regulation (increase) of IKAP
14) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.43 Pain Relevance 0
The addition of PS increased the amount of IKAP protein by 2.3 fold in FD cells treated with PS relative to untreated FD cells (Figure 3C).
Positive_regulation (increased) of IKAP protein associated with familial dysautonomia
15) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.27 Pain Relevance 0
We found that an FDA-approved food supplement, phosphatidylserine (PS), increased the amount of wild-type IKAP mRNA in FD cell lines.
Positive_regulation (increased) of IKAP mRNA associated with familial dysautonomia
16) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.73 Pain Relevance 0
PS treatment of FD cells elevated wild-type IKAP mRNA and protein levels and resulted in a cell cycle distribution similar to that of the control cells.
Positive_regulation (elevated) of IKAP mRNA associated with familial dysautonomia
17) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.75 Pain Relevance 0
A significant increase in wild-type IKAP mRNA levels and a shift towards a higher level of exon 20 inclusion was observed with an optimal concentration of 100 µM of kinetin (Figure 7A), with no toxicity observed.
Positive_regulation (increase) of IKAP mRNA associated with toxicity
18) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.69 Pain Relevance 0.03
After 24 hr of treatment the best results were obtained for cell line FDA; we observed about a 5-fold increase in the amount of wild-type IKAP mRNA after treatment with 5, 10 or 100 µg/ml PS compared to levels in FDA cells treated with the solvent only (Figure 2B).
Positive_regulation (increase) of IKAP mRNA
19) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.43 Pain Relevance 0
Sharp·PS GOLD increased the level of the wild-type IKAP mRNA at one twentieth the effective concentration of PS.
Positive_regulation (increased) of IKAP mRNA
20) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.63 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox